CN118045082A - 软性抗胆碱能酯的方法和组合物 - Google Patents

软性抗胆碱能酯的方法和组合物 Download PDF

Info

Publication number
CN118045082A
CN118045082A CN202410181296.5A CN202410181296A CN118045082A CN 118045082 A CN118045082 A CN 118045082A CN 202410181296 A CN202410181296 A CN 202410181296A CN 118045082 A CN118045082 A CN 118045082A
Authority
CN
China
Prior art keywords
compound
hydroxyacetoxy
cyclopentyl
phenyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410181296.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·S·博多尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bodor Laboratories Inc
Original Assignee
Bodor Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories Inc filed Critical Bodor Laboratories Inc
Publication of CN118045082A publication Critical patent/CN118045082A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410181296.5A 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物 Pending CN118045082A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562217362P 2015-09-11 2015-09-11
US62/217,362 2015-09-11
PCT/US2016/050385 WO2017044412A1 (en) 2015-09-11 2016-09-06 Methods and compositions for soft anticholinergic esters
CN201680065967.5A CN108348502A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680065967.5A Division CN108348502A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Publications (1)

Publication Number Publication Date
CN118045082A true CN118045082A (zh) 2024-05-17

Family

ID=58239861

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202410181296.5A Pending CN118045082A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN201680065967.5A Pending CN108348502A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181298.4A Pending CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181300.8A Pending CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201680065967.5A Pending CN108348502A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181298.4A Pending CN118021770A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物
CN202410181300.8A Pending CN118021797A (zh) 2015-09-11 2016-09-06 软性抗胆碱能酯的方法和组合物

Country Status (12)

Country Link
US (4) US11534422B2 (cg-RX-API-DMAC7.html)
EP (1) EP3347007B1 (cg-RX-API-DMAC7.html)
JP (4) JP7270958B2 (cg-RX-API-DMAC7.html)
KR (1) KR102889909B1 (cg-RX-API-DMAC7.html)
CN (4) CN118045082A (cg-RX-API-DMAC7.html)
AU (2) AU2016318595B2 (cg-RX-API-DMAC7.html)
ES (1) ES2942361T3 (cg-RX-API-DMAC7.html)
IL (1) IL257970B (cg-RX-API-DMAC7.html)
MX (1) MX388831B (cg-RX-API-DMAC7.html)
MY (1) MY197265A (cg-RX-API-DMAC7.html)
WO (1) WO2017044412A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201801685B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044965A (zh) * 2018-10-17 2018-12-21 广州大光制药有限公司 格隆溴铵的眼用药物组合物及医药用途
US20230149349A1 (en) * 2020-03-03 2023-05-18 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide
CN118119392A (zh) 2021-11-01 2024-05-31 犹他大学研究基金会 用于治疗流涎的组合物和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US9198897B2 (en) * 2005-01-19 2015-12-01 Neurohealing Pharmaceuticals, Inc. Methods and compositions for decreasing saliva production
ATE529399T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
EP1957451B1 (en) 2005-11-10 2011-10-19 Nicholas S. Bodor Soft anticholinergic zwitterions
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010530902A (ja) 2007-06-22 2010-09-16 サイエル ファーマ,インコーポレイティド 流涎症治療のためのグリコピロレートを含む経皮送達システム
US8628729B2 (en) 2008-03-27 2014-01-14 President And Fellows Of Harvard College Three-dimensional microfluidic devices
JP6223543B2 (ja) * 2013-03-15 2017-11-01 ボドール ラボラトリーズ, インコーポレイテッド 多汗症の処置のための抗コリン作用性グリコピロレートエステル

Also Published As

Publication number Publication date
US12458625B2 (en) 2025-11-04
MY197265A (en) 2023-06-08
WO2017044412A1 (en) 2017-03-16
HK1255558A1 (en) 2019-08-23
ES2942361T3 (es) 2023-05-31
JP2022132446A (ja) 2022-09-08
JP2018526420A (ja) 2018-09-13
KR20180061220A (ko) 2018-06-07
JP2021001238A (ja) 2021-01-07
AU2021204306A1 (en) 2021-07-22
US20240261262A1 (en) 2024-08-08
CN108348502A (zh) 2018-07-31
JP2023164671A (ja) 2023-11-10
EP3347007B1 (en) 2023-03-29
US11951093B2 (en) 2024-04-09
JP7270958B2 (ja) 2023-05-11
CN118021797A (zh) 2024-05-14
IL257970A (en) 2018-05-31
AU2016318595B2 (en) 2021-07-08
IL257970B (en) 2021-04-29
CN118021770A (zh) 2024-05-14
KR102889909B1 (ko) 2025-11-24
US20180250265A1 (en) 2018-09-06
JP7723417B2 (ja) 2025-08-14
US20220401410A1 (en) 2022-12-22
ZA201801685B (en) 2023-12-20
EP3347007A1 (en) 2018-07-18
EP3347007A4 (en) 2019-05-08
MX388831B (es) 2025-03-20
US11534422B2 (en) 2022-12-27
AU2021204306B2 (en) 2023-11-09
US20260108491A1 (en) 2026-04-23
AU2016318595A1 (en) 2018-04-26
CA2998357A1 (en) 2017-03-16
MX2018003002A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US12458625B2 (en) Methods and compositions for soft anticholinergic esters
JP5941558B2 (ja) シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
TWI554498B (zh) 置入口腔的劑型
AU2007227614B2 (en) Solid dosage form containing a taste masked active agent
JP5786195B2 (ja) 舌下フィルム
JP2016525572A (ja) 経口分散性フィルム
WO2018004576A2 (en) A fast acting orally disintegrating film for administration of local anesthesia
JP2000063268A (ja) 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤
HK40110882A (en) Methods and compositions for soft anticholinergic esters
HK40110881A (en) Methods and compositions for soft anticholinergic esters
HK40111398A (en) Methods and compositions for soft anticholinergic esters
CA2998357C (en) Compositions comprising a soft anticholinergic ester
AU2016318594A1 (en) Methods and compositions for soft anticholinergic zwitterions
HK1255558B (en) Methods and compositions for soft anticholinergic esters
JP2001002590A (ja) 口腔粘膜付着型徐放性錠剤
Menra et al. A REVIEW ON BUCCAL FILM: AN INOVATIVE DOSAGE FORM.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111398

Country of ref document: HK